Wikipedia -WSS

Wikipedia

author：comprehensive 2025-09-27 13:03:02 - browse：576

An AstraZeneca sign at ESMO in Madrid. — An AstraZeneca ad at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months.

On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

The trial, detailed here in a prime session at the annual meeting of the European Society for Medical Oncology, is testing a therapy called datopotamab deruxtecan, or Dato-DXd, in advanced or metastatic non-small cell lung cancer in patients who already tried at least first-line treatments. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Free Covid tests will again be offered to all U.S. households

entertainment

WSS

Abridge raises $150m as clinical notes automation market heats up

Surprise medical billing ban raises prices elsewhere

PBMs drew scrutiny in House hearing — and so did pharma

Medicare Advantage enrollment hits roughly 33.4 million

Grad students accuse University of California of wage theft

Congress may force more Covid

explore

Wikipedia

explore

Activists slam private health insurers over coverage restrictions

Assistant physicians can help address the primary care shortage

Medical records are filled with copy

A new drug could help frostbite victims avoid its ravages

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Opioid cravings were reduced by anti

Anesthesiologist group: stop taking Ozempic before surgery

New study raises questions about niacin and heart health

The cancer drug shortage isn’t new — and neither are the solutions

Abridge raises $150m as clinical notes automation market heats up

hotspot

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Fed up with FDA, ALS advocates consider a take

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Free Covid tests will again be offered to all U.S. households

Fed up with FDA, ALS advocates consider a take

Obamacare plans could cover weight loss drugs

entertainment

hotspot

knowledge

hotspot